drugset / Trial / NCT00084253

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

NCT00084253

Phase 4 Completed 200 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if 300 mg of ATV plus 100 mg of ritonavir (RTV) works as well as 400 mg of ATV alone as part of a regimen with stavudine XR and lamivudine to slow or stop the progression of HIV infection in patients who have never used anti-HIV drugs.

Timeline

Start
2004-06
Primary completion
2006-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Atazanavir Other / unclassified 400 mg Oral
Comparator Lamivudine Other / unclassified 300 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral
Comparator Stavudine Other / unclassified 100 mg Oral